Balanced two-stage designs for phase II clinical trials

Clinical Trials

Volumn 4, Issue 5, 2007, Pages 514-524

  Ye, Fei ^a   Shyr, Yu ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL ERROR; ARTICLE; CORRELATION ANALYSIS; HYPOTHESIS; INFORMATION PROCESSING; METHODOLOGY; NULL ALLELE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SAMPLE SIZE; SIMULATION; STATISTICAL PARAMETERS;

DATA INTERPRETATION, STATISTICAL; HUMANS; MEDICAL ONCOLOGY; RESEARCH; RESEARCH DESIGN; SAMPLE SIZE;

EID: 36549021476     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774507084102     Document Type: Article

References (9)

1. Heitjan DF. Bayesian interim analysis of phase II cancer clinical trials. Statistical Medcine 1997; 16: 1791-802.
2. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clini Trials 1989; 10: 1-10.
3. Sargent DJ, Sloan JA, Cha SS. Sample size and design considerations for phase II clinical trials with correlated observations. Controlled Clini Trials 1999; 20: 242-52.
4. Bellissant E, Benichou J, Chastang C. Design and analysis of phase II trials in oncology with a group sequential method, the triangular test. Therapie 1991; 46: 21-7.
5. Sebille V, Bellissant E. Sequential methods and group sequential designs for comparative clinical trials. Fundamental Clini Pharmacol 2003; 17: 505-16.
6. Jennison C. Efficient group sequential tests with unpredictable group sizes. Biometrika 1987; 74: 155-66.
7. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clin. Trials (3rd ed.) Springer Verlag, 1998.
8. Gehan EA. The determination of the number of participants required in a follow-up trial of a new chemotherapeutic agent. J Chronic Disease 1961; 13: 346-53.
9. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-51.